noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

AWF - African Wildlife Foundation

Nsembe Balombo’s Journey: Investing in Communities to Build Resilience[...]
Amplitude Inc.

Statement of Changes in Beneficial Ownership (Form 4)
Amplitude Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Healthcare

Praxis Precision Medicines Inc.

07/07/2026 | Press release | Distributed by Public on 07/07/2026 15:05

Material Event (Form 8-K)

Item 8.01. Other Events.

On July 7, 2026, Praxis Precision Medicines, Inc. (the "Company") announced that the Company entered into a research collaboration and license agreement (the "Agreement") with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems ("Remagine"), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine's proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide, complementing the Company's lead oral program. A transdermal option is intended to broaden the population ulixacaltamide can reach, while strengthening ulixacaltamide's competitive positioning and extending the long-term value of the franchise. The Company has also made an equity investment in Remagine, underscoring the companies' shared commitment to quickly advancing the program.

Praxis Precision Medicines Inc. published this content on July 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 07, 2026 at 21:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]